Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease

Our findings suggest that αSyn co-pathology, detectable via CSF-based SAAs, is more prevalent in advanced AD and contributes to the development of aggregated tau pathology thereby driving faster cognitive decline. This highlights that a-Syn co-pathology may specifically accelerate amyloid-driven tau pathophysiology in AD, underscoring the need to consider αSyn in AD research and treatment strategies.

Authors

Institutions

Publication Details

Journal
Molecular Neurodegeneration
Published
2025-03-18
DOI
https://doi.org/10.1186/s13024-025-00822-3
Citations
32
Primary Topic
Alzheimer's disease research and treatments
Type
article
Field-Weighted Citation Impact
36.09

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease

Alexander Bernhardt, Amir Dehsarvi, Rik Ossenkoppele, Anna Dewenter et al.
32 citations
Molecular Neurodegeneration
Alzheimer's disease research and treatments
36.09
article

Alpha synuclein co-pathology is associated with accelerated amyloid-driven tau accumulation in Alzheimer’s disease

Alexander Bernhardt, Amir Dehsarvi, Rik Ossenkoppele, Anna Dewenter, Anna Steward, Fabian Wagner, Johannes Levin, Carla Palleis, Matthias Brendel, Johannes Gnörich, Sebastian Niclas Roemer, Fabian Hirsch, Günter U. Höglinger, Zeyu Zhu, Michael Schöll, Lukas Frontzkowski, Nicolai Franzmeier, Davina Biel, Hannah de Bruin, Felix Strübing, Julia Pescoller
article en
32 citations

Abstract

Our findings suggest that αSyn co-pathology, detectable via CSF-based SAAs, is more prevalent in advanced AD and contributes to the development of aggregated tau pathology thereby driving faster cognitive decline. This highlights that a-Syn co-pathology may specifically accelerate amyloid-driven tau pathophysiology in AD, underscoring the need to consider αSyn in AD research and treatment strategies.

Molecular NeurodegenerationVol. 20(1)
Lund University (SE), Sahlgrenska University Hospital (SE), German Center for Neurodegenerative Diseases (DE), LMU Klinikum (DE), Amsterdam Neuroscience (NL), Munich Cluster for Systems Neurology (DE), UK Dementia Research Institute (GB), National Hospital for Neurology and Neurosurgery (GB), University College London (GB), Ludwig-Maximilians-Universität München (DE), Vrije Universiteit Amsterdam (NL), University of Gothenburg (SE)
Alzheimer's Association, BrightFocus Foundation, Alzheimer's Disease Neuroimaging Initiative, Göteborgs Universitet, Parkinsonfonden
Good health and well-being
Openalex Percentile: Top 0%
Alzheimer's disease research and treatments
36.09
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.